Learn More
The presence of circulating tumor cells (CTC) from various cancers has provided a wealth of information and possibilities. As the role of CTC detection in the treatment assessment of metastatic breast cancer becomes standard, there is interest in applying this tool in cancer vaccine development and clinical trial monitoring. Since we lack a proven(More)
e11126 Background: Circulating tumor cells (CTC) may have a role as a prognostic marker and in monitoring therapeutic response in breast cancer (BrCa) patients. We are conducting a prospective, randomized phase II trial evaluating the HER2 peptide vaccines AE37 and GP2 in the adjuvant setting. AE37 is the Ii-Key hybrid of the AE36 peptide (HER2: 776-790)(More)
  • 1